Legal Representation
Attorney
Brent E.. Routman
USPTO Deadlines
Next Deadline
1798 days remaining
Section 71 Declaration Due (Principal Register 66a) (Based on registration date 20241203)
Due Date
December 03, 2030
Grace Period Ends
June 03, 2031
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
18 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Dec 3, 2024 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| Dec 3, 2024 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Oct 1, 2024 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Oct 1, 2024 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Sep 11, 2024 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Aug 23, 2024 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Aug 23, 2024 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Aug 23, 2024 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Aug 23, 2024 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Jul 15, 2024 | RFNT | P | REFUSAL PROCESSED BY IB | Loading... |
| Jun 24, 2024 | RFCS | P | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | Loading... |
| Jun 24, 2024 | RFRR | P | REFUSAL PROCESSED BY MPU | Loading... |
| Jun 14, 2024 | RFCR | E | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | Loading... |
| Jun 3, 2024 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| May 18, 2024 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Feb 27, 2024 | MAFR | O | APPLICATION FILING RECEIPT MAILED | Loading... |
| Feb 23, 2024 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Feb 22, 2024 | REPR | M | SN ASSIGNED FOR SECT 66A APPL FROM IB | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations, namely, prescription and non-prescription pharmaceutical preparations and drugs for the treatment of respiratory system diseases and disorders, cardiovascular diseases, central nervous system diseases and disorders, namely, brain diseases, spinal cord diseases and injuries, movement and seizure disorders, genitourinary diseases and disorders, namely, pelvic diseases, urological diseases and sexually transmitted diseases, gynecological diseases and disorders, gastrointestinal diseases and disorders, musculoskeletal system diseases and disorders, namely, connective tissue diseases, bone diseases, back pain, fractures, sprains, cartilage injuries, endocrine and metabolic diseases and disorders, namely, hyperlipidemia, hypercalcemia, diabetes, gout, anemia, cholestatic liver diseases, namely, primary biliary cirrhosis (PBC), skin diseases and disorders, namely, dermatitis and fungal diseases, ocular diseases and disorders, allergies, cold, cough, sinus diseases and disorders, hypertension, sexual diseases and disorders, prostate diseases and disorders, cancer, obesity, inflammation and inflammatory diseases and disorders, namely, inflammatory bowel diseases, inflammatory connective tissue diseases, infectious diseases and disorders, namely, respiratory infections, eye infections, topical infections, immunological diseases, namely, autoimmune diseases, immunologic deficiency syndrome, viral diseases and disorders, namely, herpes, hepatitis, acquired immune deficiency syndrome (aids), parasitic diseases, namely, malaria, parasitic infections, namely, intestinal worms, psychiatric diseases and disorders, namely, mood disorders, anxiety disorders, cognitive disorders, schizophrenia and bipolar disorders, dental and oral diseases, namely, mouth diseases, esophageal diseases and toothaches, motion sickness, carpal tunnel syndrome and pain, namely, headaches, migraines, back pain, pain from burns, neuropathic pain, chronic pain associated with osteoarthritis of the knee, transplant rejection, hyperfibrinolysis, hereditary angioedema, drug abuse and biosimilar biologic drugs for the treatment of inflammatory diseases and disorders, namely, inflammatory connective tissue diseases and inflammatory bowel diseases, skin diseases and disorders, namely, psoriasis and hidradenitis suppurativa, ocular diseases and disorders, namely, inflammation of the uvea or uveal tract; natural health product preparations, namely, dietary supplements, nutritional supplements and herbal supplements for general health and well-being, namely, food supplements containing natural plant extracts, natural algae, natural algae extracts and fungus extracts, vitamins, mineral supplements, amino acids, fatty acids, dietary fibre, probiotics dietary supplements, enzyme and protein supplements in powder, capsule, tablet and liquid form, all for maintaining brain health, for neuroprotection, for improving or preserving cognition, memory and brain function; vitamins and nutritional supplements, namely, vitamins and nutritional supplements in the form of calcium, electrolyte drinks, energy bars, energy drinks, juice drinks, lecithin, minerals, vitamins for pharmaceutical, medicinal and therapeutic use
Class 035
Business management with relation to strategy, marketing, production, personnel and retail sale matters of pharmaceutical preparations, drugs and biosimilar biologic drugs for promoting optimal health of the human body, namely, prescription and non-prescription pharmaceutical preparations, vitamins and nutritional supplements
Additional Information
Design Mark
The mark consists of a circular design interrupted by a curved opening near the bottom-center of the design, to the left of the stylized wording "JAMP PHARMA".
Classification
International Classes
005
035
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"PHARMA"